Department of Thyroid and Breast Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Endocrinol (Lausanne). 2022 Aug 5;13:944758. doi: 10.3389/fendo.2022.944758. eCollection 2022.
Overtreatment of papillary thyroid microcarcinoma (PTMC) has become a common concern. This study aimed to compare clinicopathological features between PTMC and papillary thyroid carcinoma (PTC) and to explore whether surgery can confer significant survival benefits in all patients with PTC or PTMC.
Data of 145,951 patients with PTC registered in Surveillance, Epidemiology, and End Results (SEER) database and 8,751 patients with PTC in our institution were retrospectively collected. Patients with tumors less than 10 mm in diameter were classified as PTMC cohort and the rest as PTC cohort. Clinicopathological features between PTMC and PTC were compared on the basis of SEER cohort and validated with institutional data. Survival analysis was conducted to explore the effect of surgery on the prognosis of patients. To minimize potential confounders and selection bias, we performed propensity score matching (PSM) analysis to match more comparable cohorts.
Compared with PTC, PTMC exhibited the following characteristics: more common in women and whites, older age at diagnosis, lower proportion of follicular variants, intraglandular dissemination, extraglandular and capsular invasion, higher proportion of multifocality, fewer lymph node and distant metastases, and higher cancer-specific survival (CSS) and overall survival (OS) (all -value < 0.05). Regarding treatment, patients with PTMC received a lower proportion of radiotherapy, chemotherapy, and total thyroidectomy but a higher proportion of lobectomy and/or isthmectomy. There was no significant difference in CSS for patients with PTMC at stage T1N0M0 with or without surgery ( = 0.36).
Generally, PTMC showed higher biological indolence than PTC, which meant a higher survival rate for patients in both OS and CSS. For patients with PTMC at staged T1N0M0, active surveillance (AS) may be a potentially feasible management strategy. However, the maintenance of good medical compliance and the management of psychological burden cannot be ignored for patients included in AS.
甲状腺乳头状微小癌(PTMC)的过度治疗已成为一个普遍关注的问题。本研究旨在比较 PTMC 和甲状腺乳头状癌(PTC)的临床病理特征,并探讨手术是否能使所有 PTC 或 PTMC 患者获得显著的生存获益。
回顾性收集了监测、流行病学和最终结果(SEER)数据库中 145951 例 PTC 患者和我院 8751 例 PTC 患者的数据。将肿瘤直径小于 10mm 的患者分为 PTMC 组,其余为 PTC 组。根据 SEER 队列比较 PTMC 和 PTC 的临床病理特征,并通过机构数据进行验证。生存分析用于探讨手术对患者预后的影响。为了最大限度地减少潜在的混杂因素和选择偏倚,我们进行了倾向评分匹配(PSM)分析,以匹配更具可比性的队列。
与 PTC 相比,PTMC 具有以下特征:女性和白人更常见,诊断时年龄更大,滤泡变体比例更低,腺内播散,腺外和包膜侵犯,多灶性比例更高,淋巴结和远处转移更少,癌症特异性生存率(CSS)和总生存率(OS)更高(均 P < 0.05)。在治疗方面,PTMC 患者接受放疗、化疗和全甲状腺切除术的比例较低,但接受甲状腺叶切除术和/或峡部切除术的比例较高。在 T1N0M0 期有或无手术的 PTMC 患者的 CSS 无显著差异( P = 0.36)。
一般来说,PTMC 比 PTC 表现出更高的生物学惰性,这意味着患者在 OS 和 CSS 方面的生存率更高。对于 T1N0M0 期的 PTMC 患者,主动监测(AS)可能是一种潜在可行的管理策略。然而,对于纳入 AS 的患者,不能忽视良好的医疗依从性的维持和心理负担的管理。